<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661451</url>
  </required_header>
  <id_info>
    <org_study_id>TAVR Unload</org_study_id>
    <nct_id>NCT02661451</nct_id>
  </id_info>
  <brief_title>Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)</brief_title>
  <official_title>Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure: A Randomized Trial (TAVR UNLOAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Research Foundation, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Biomedical Associates LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiovascular Research Foundation, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety and efficacy of transcatheter aortic
      valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as
      compared with OHFT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Death within 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Hierarchical occurrence within one year of:
All-cause death
Disabling Stroke
Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke
Change in KCCQ relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disabling Stroke within 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Hierarchical occurrence within one year of:
All-cause death
Disabling Stroke
Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke
Change in KCCQ relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke within 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Hierarchical occurrence within one year of:
All-cause death
Disabling Stroke
Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke
Change in KCCQ relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) relative to baseline within 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Hierarchical occurrence within one year of:
All-cause death
Disabling Stroke
Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke
Change in KCCQ relative to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death, disabling stroke and renal replacement therapy at 30 days, 6 months and 12 months</measure>
    <time_frame>30 days, 6 months and 1 year</time_frame>
    <description>Composite of all-cause death, disabling stroke and renal replacement therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR (with SAPIEN 3 THV) and OHFT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter heart valve and Optimal Heart Failure Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OHFT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Heart Failure Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3 THV</intervention_name>
    <arm_group_label>TAVR (with SAPIEN 3 THV) and OHFT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Optimal Heart Failure Therapy</intervention_name>
    <arm_group_label>TAVR (with SAPIEN 3 THV) and OHFT</arm_group_label>
    <arm_group_label>OHFT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. NYHA class ≥ 2

          2. NT-proBNP &gt; 1500 pg/mL (or BNP &gt; 400 pg/mL) or hospitalization for HF within the last
             year

          3. Under appropriate guideline-directed HF therapy (including cardiac resynchronization
             therapy) for a minimum of 3 months.

          4. Moderate AS defined by (all must be met):

               -  Mean trans-aortic gradient (MG) ≥ 20 mmHg and &lt; 40 mmHg at rest and with
                  dobutamine-stress echocardiography (DSE)

               -  Aortic valve area (AVA) &gt; 1.0 cm2 with DSE

               -  Aortic valve area (AVA) ≤1.5 cm2 at rest

          5. Left ventricular (LV) ejection fraction (EF) &lt; 50%

          6. Anatomically suitable for transfemoral TAVR with the SAPIEN 3 THV

        Exclusion Criteria:

          1. LVEF &lt; 20% or persistent need for intravenous inotropic support

          2. Hospitalization for acute decompensated HF within 2 weeks prior to randomization

          3. Cardiac resynchronization therapy device implantation within 3 months prior to
             randomization

          4. Coronary artery revascularization (PCI or CABG) within 3 months prior to
             randomization

          5. In need and suitable for revascularization per heart team consensus

          6. Severe aortic regurgitation

          7. Congenital unicuspid or congenital bicuspid aortic valve

          8. Concomitant non-aortic valvular disease with a formal indication for valve surgery
             per established guidelines (ESC/ACC/AHA)

          9. Previous aortic valve replacement (mechanical or bioprosthetic)

         10. Severe mitral regurgitation due to degenerative mitral disease (primary MR)

         11. Previous stroke with permanent disability (modified Rankin score ≥ 2)

         12. Chronic obstructive pulmonary disease GOLD 4

         13. Severe chronic kidney disease: glomerular filtration rate &lt; 30 mL/min by MDRD or need
             for renal replacement therapy

         14. Gastrointestinal bleeding within the past 3 months

         15. Liver cirrhosis Child-Pugh C

         16. Active systemic infection, including active endocarditis

         17. Unwilling to accept blood transfusion

         18. Evidence of intracardiac mass, thrombus, or vegetation

         19. Absence of minimum amount of aortic valve calcification necessary for TAVR with the
             SAPIEN 3 THV

         20. Hypersensitivity or contraindication to clopidogrel, aspirin, or to oral
             anticoagulation if indicated (eg, subject in atrial fibrillation).

         21. Sensitivity to contrast media which cannot be adequately pre-medicated

         22. Women of child-bearing potential

         23. Clinical signs of dementia

         24. Other medical, social, or psychological conditions that precludes appropriate consent
             and follow-up

         25. Life expectancy &lt; 2 years due to cancer or other non-cardiac chronic diseases

         26. Unwillingness to undergo follow-up investigations

         27. Currently participating in an investigational drug or another device trial that has
             not reached its primary endpoint (excluding registries).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Ben Yehuda, MD</last_name>
    <email>obenyehuda@crf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Santiago</last_name>
    <email>bsantiago@crf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center/NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>January 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
